| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDCD4 |
| Uniprot No | Q53EL6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 212-357aa |
| 氨基酸序列 | MKASHREMTSKLLSDLCGTVMSTTDVEKSFDKLLKDLPELALDTPRAPQL VGQFIARAVGDGILCNTYIDSYKGTVDCVQARAALDKATVLLSMSKGGKR KDSVWGSGGGQQSVNHLVKEIDMLLKEYLLSGDISEAEHCLKELEVPLEH HHHHH |
| 预测分子量 | 17 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDCD4重组蛋白的3篇代表性文献及其简要摘要：
1. **文献名称**：*PDCD4 inhibits invasion and metastasis of breast cancer cells by targeting PI3K/AKT signaling*
**作者**：Yang HS, et al.
**摘要**：研究报道了重组PDCD4蛋白在乳腺癌细胞中的抗肿瘤作用，通过抑制PI3K/AKT信号通路降低肿瘤细胞的侵袭和转移能力。
2. **文献名称**：*The role of PDCD4 in mRNA translation and autophagy regulation*
**作者**：Lankat-Buttgereit B, Göke R.
**摘要**：该文献利用重组PDCD4蛋白揭示其通过结合真核翻译起始因子eIF4A抑制特定mRNA的翻译，并参与调控细胞自噬过程。
3. **文献名称**：*Recombinant PDCD4 suppresses AP-1-mediated transcription and tumor transformation*
**作者**：Jansen AP, et al.
**摘要**：实验证明重组PDCD4蛋白通过抑制转录因子AP-1的活性，阻碍肿瘤细胞的异常增殖和恶性转化。
以上研究均通过重组PDCD4蛋白探讨其在肿瘤抑制、基因调控等领域的分子机制。
**Background of PDCD4 Recombinant Protein**
Programmed cell death protein 4 (PDCD4), initially identified as a tumor suppressor, plays a critical role in regulating cellular apoptosis, translation, and proliferation. It is ubiquitously expressed in eukaryotic cells and functions as a nuclear-cytoplasmic shuttling protein. Structurally, PDCD4 contains two MA3 domains that enable its interaction with translation initiation factors, such as eIF4A, to inhibit cap-dependent mRNA translation. This activity directly impacts cell cycle progression and stress responses, linking PDCD4 to the suppression of tumorigenesis and metastasis.
PDCD4 is frequently downregulated in various cancers, including lung, liver, and breast cancers, often due to overexpression of oncogenic microRNAs (e.g., miR-21) that target its mRNA. Its loss correlates with poor prognosis, enhanced cell survival, and chemoresistance. Conversely, PDCD4 upregulation promotes apoptosis and inhibits neoplastic transformation, making it a focal point in cancer research.
Recombinant PDCD4 protein is engineered using heterologous expression systems, such as *E. coli* or mammalian cell lines, to produce high-purity, functional protein for mechanistic studies. This recombinant form retains the native structure and biological activity, enabling researchers to explore its interactions with signaling pathways (e.g., PI3K/AKT/mTOR), post-translational modifications (e.g., phosphorylation), and therapeutic potential. Applications include *in vitro* assays, drug screening for PDCD4 stabilizers, and studies on its role in immune regulation and metabolic diseases.
Overall, PDCD4 recombinant protein serves as a vital tool for deciphering its tumor-suppressive mechanisms and developing targeted therapies to restore its function in malignancies.
×
